Hormone-free option
Safety focused
Women’s Health Clinic FAQ
How long do the results of intimate polynucleotides last?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The important first step is confirming the symptom cause, not choosing an injectable by name.
Direct answer
Results from intimate polynucleotides are gradual and not indefinite. Hydration or comfort changes may be noticed earlier, while tissue-quality changes linked with collagen, elastin and repair signalling take longer and vary between patients. Duration depends on the underlying diagnosis, age, hormonal environment, product, treatment plan, aftercare and whether GSM or vulval conditions are also being managed. Maintenance should be based on review and response, not automatic repeat treatment.
Your clinician should review symptoms, medical history, allergies, medicines, cancer history where relevant, alternatives, expected benefits, limitations and aftercare before deciding whether treatment fits.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether intimate polynucleotides are suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Modality
Non-hormonal, regenerative injectable therapy.
Mechanism
Functions through biostimulation and hydration of the extracellular matrix rather than acting as a mechanical volumizing filler.
Versus PRP
Provides a standardised, off-the-shelf formulation with highly predictable rheology, distinguishing it from the autologous variability of Platelet-Rich Plasma (PRP).
Target Area
Specifically conditions the superficial "comfort layer" (mucosa and vestibule) rather than the deep structural layers of the pelvis.
Important safety note
Common Side Effects: Short-term, mild localised reactions include pinpoint bruising, temporary redness, swelling, and a sensation of fullness or tenderness lasting 24 to 72 hours.
Allergy
Evidence
Aftercare
Alternatives
Detailed answer
Results are gradual
Hydration may be noticed earlier, while tissue remodelling takes longer and varies.
Maintenance after review
Repeat treatment should depend on response, diagnosis and goals, not a resolved timetable alone.
Evidence
Symptoms
Alternatives
What it means
Not a Structural resolve: Polynucleotides do not mechanically "tighten" the vagina, nor do they correct deep fascial defects, pelvic organ prolapse, or scar geometry.
Why symptoms matter
Adjunct Therapy: They are intended as an adjunct to, not a replacement for, standard foundational care.
Evidence limits
Evidence is encouraging in selected areas, but intimate-use claims should remain cautious and assessment-led.
Treatment fit
Clinical Setting: Procedures are performed in an outpatient clinic environment by qualified medical professionals or nurse prescribers.
What this means in practice
Clinical Setting: Procedures are performed in an outpatient clinic environment by qualified medical professionals or nurse prescribers.
Treatment Course: Optimal outcomes usually require a primary series of 2 to 3 sessions, spaced approximately 2 to 4 weeks apart.
Patient safety
Why diagnosis comes first
Many intimate symptoms overlap. The right treatment depends on whether the issue is GSM, infection, vulval skin disease, scarring, pelvic-floor guarding, medication effect or another cause.
It checks the cause
Not a Structural resolve: Polynucleotides do not mechanically "tighten" the vagina, nor do they correct deep fascial defects, pelvic organ prolapse, or scar geometry.
It protects safety
Common Side Effects: Short-term, mild localised reactions include pinpoint bruising, temporary redness, swelling, and a sensation of fullness or tenderness lasting 24 to 72.
It reviews alternatives
Moisturisers, lubricants, local ooestrogen, pelvic-floor care or specialist review may be more appropriate first.
It sets expectations
Polynucleotides are gradual tissue-support treatments, not instant resolves or promised outcomes.
Non-hormonal does not mean automatic
A hormone-free option may still be unsuitable if there is infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
Good care explains product source, treatment route, alternatives, limits, aftercare and when another medical pathway is safer.
Considerations
What to consider
Treatment planning should include diagnosis, symptom pattern, allergy risk, medicines, consent, realistic timelines and aftercare.
Consultation priorities
A consultation should review symptoms, medical history, fish allergy, infection risk, bleeding risk, pregnancy status, expectations and alternatives.
Consent
Aftercare
Review
Before treatment
Assessment: The journey begins with a thorough medical consultation to review symptom patterns, rule out red flags, and screen for contraindications (like fish allergies).
During care
optimisation: Foundational care (e.g., hydration and local oooestrogen) is supportd before procedural interventions are initiated.
Aftercare
Treatment Phase: The patient undergoes the primary course of 2 to 3 injection sessions, with personalised aftercare instructions emphasizing pelvic rest and hygiene.
When to reassess
If symptoms persist, worsen or do not match expectations, reassessment is safer than repeating treatment automatically.
Practical expectations
Treatment Course: Optimal outcomes usually require a primary series of 2 to 3 sessions, spaced approximately 2 to 4 weeks apart.
Costs and treatment plans should be confirmed before booking; do not rely on generic package claims.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments used for gradual tissue-quality support, not instant volume.
Myth: hormone-free means suitable for everyone
Reality: fish allergy, infection, bleeding, pregnancy, recent surgery and unclear pain can make treatment unsuitable.
Myth: results are promised
Reality: response varies and should be reviewed before repeating treatment.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be better for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting an injectable treatment.
Are red flags absent?
Active infection, unexplained bleeding, severe pain or new vulval changes should be checked first.
Are alternatives clear?
Ask what conservative, hormonal, pelvic-floor or specialist options may be more appropriate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, goals are realistic, red flags are absent and aftercare is understood.
No red flags
Review plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, pregnancy, severe fish allergy, recent pelvic surgery, severe pain or changing vulval skin.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips, tongue or face, breathing difficulty, widespread hives, faintness or collapse needs urgent help.
Bleeding or new skin change
New post-menopausal bleeding, ulcers, changing white plaques, unusual discharge or visible blood in urine should be assessed.
Infection signs
Fever, pus, spreading redness, worsening swelling or feeling unwell after a procedure needs prompt advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support assessment-led, evidence-aware patient information and help separate clinical care from promotional claims.
PubMed: PN/HA intradermal treatment for vulvovaginal atrophy
This pilot study is directly relevant to PN/HA use in vulvovaginal atrophy and supports cautious evidence-aware discussion.
NICE menopause recommendations
NICE provides UK guidance for GSM, vaginal ooestrogen, non-hormonal care and cancer-history decision-making.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether intimate polynucleotides may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 68 imported records. Additional reviewed material included peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
